From Carl – 4/16…….

I sold about ¾ of my position in THMO today, up over 100% from last purchase.  There is still one remaining big catalyst possible short term related to CV.  If they receive a contract like WORX has it could trade higher.  I believe the recent announcement about research on a treatment has little value at this point.  The drugs being developed by GILD, ENLV and others have far greater short term potential.